Recombinant human factor VIIa (rFVIIa) is often used off -label in massively bleeding patients. A recent review of use in the USA [1] and a meta-analysis of studies for nonapproved indications [2] document the frequent use of rFVIIa in a variety of clinical conditions charac terized by a real risk of death or major morbidity from exsanguination.
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Th e literature demonstrates an association between use of rFVIIa and increased risk of arterial thromboembolic complications [3] . Th is increased risk is, of course, a predictable side eff ect of a procoagulant drug, and can actually be regarded as proof of its physiologic eff ect. Th ese recent studies have raised doubts about the advisability of giving this product to massively bleeding patients, and have prompted some hospitals to ban or restrict the use of the drug in hemorrhaging patients. Yet the effi cacy of rFVIIa as a hemostatic agent is actually well established. Perhaps the numerous case reports on the cessation of bleeding will not be entirely convincing to all defenders of evidence-based medicine, but the results from prospective randomized, placebo-controlled trials should be.
Two double-blinded randomized, placebo-controlled trials have convincingly demonstrated that adminis tration of rFVIIa in massive bleeding can reduce the need for blood transfusions [4, 5] . In the fi rst trial, red blood cell transfusion was signifi cantly reduced in patients with blunt trauma. Moreover, just 14% of rFVIIa-treated blunt trauma patients received massive transfusions compared with 33% of placebo-treated patients (P = 0.03); in penetrat ing trauma, 19% of the placebo-treated patients received massive transfusions compared with only 7% of the treated group (P = 0.08). In the second trial, which was conducted to examine the 30-day mortality of patients receiving rFVIIa, the number of units of red blood cells administered to blunt trauma patients (the majority of patients studied) was signifi cantly less in rFVIIa-treated patients than in placebo-treated patients (6.9 vs. 8.9 units, P = 0.04). Th e same was true for the number of units of fresh frozen plasma administered (4.7 vs. 6.9, P <0.01).
Despite decreasing blood use, this latter study was not able to demonstrate a signifi cant reduction in mortalitythe primary endpoint -with rFVIIa use because the overall mortality in this entire cohort of severely injured patients was only 11%, and the trial had been powered based on the observed historical mortality of 25 to 30% in similarly injured patients [5] . Th is pivotal trial was therefore stopped early, for scientifi c futility. Th e authors attributed the overall decrease in mortality of the entire cohort to advancing global standards in trauma care and to the meticulous application of evidence-based principles for resuscitation, transfusion and critical care management to all patients.
In these circumstances, especially bearing in mind the heterogeneity of trauma patients, it is virtually impossible Abstract Trauma is a major cause of death worldwide, with some 30% of deaths associated with hemorrhage. Rapid control of bleeding in such patients is thus an essential aspect of trauma care. Recombinant human factor VIIa is sometimes used off -label in massively bleeding patients and has been demonstrated in two randomized trials to signifi cantly reduce the need for blood transfusions. Whether this translates into improved outcomes has not been determined, most notably because mortality appears to be much lower than in the past as a result of improved general care of trauma patients. In this setting it may be increasingly diffi cult to demonstrate that any intervention can infl uence survival since the number of patients needed for suffi cient power is so high and the duration needed for recruitment of the patients too long. In the present commentary, we refl ect on how we can move forward in the management of severely bleeding trauma patients in the current environment.
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to demonstrate a reduction in mortality. Th e number of patients that would be required becomes prohibitive, as does the amount of time that would be needed to perform such a study: 573 patients were recruited over 3 years in the CONTROL study [5] . During prolonged study periods like this, important practices may change, infl uencing outcomes. Similarly, global improvements in the management of acute respiratory failure and decreases in permanent renal failure have made the observation of changes in major morbidities in these populations diffi cult.
Th ese observations raise two important issues. First, will it be possible to conduct trials in massively bleeding patients or in polytrauma victims? If we cannot demonstrate a reduction in mortality or morbidity rates, what should be the endpoints of further studies? What kinds of studies should we propose in order to defi ne the place of rFVIIa or the newer procoagulants that are now emerging? Second, what can we reasonably do the next time we are about to lose a young trauma victim to exsanguination? Should we give rFVIIa and risk being accused of off -label use of a drug without an accepted benefi t-risk profi le, or should we deny the patient the benefi t of a potentially life-saving product that clearly reduces bleeding?
What the clinician needs is an understanding of risks and benefi ts that can be artfully applied to the care of individual patients. Clearly, almost any therapy is justifi ed at some level of risk of patient death, no matter how unlikely it is to succeed. But how should this risk be assessed? How should imminent death be weighed against the risk of future complications, especially if they can be prevented or treated in a surviving patient?
Experienced high-volume trauma centers, including British and American military hospitals in Iraq and Afghani stan, have seen their use of rFVIIa fall in recent years (see Figure 1 in [1] ). Th is fall in use is thought to be the result of an improved understanding of damage control resuscitation, and of a natural centering of the pendulum of enthusiasm for rFVIIa. But use has not fallen to zero. Th ere remain situations -at least in the practice of the most experienced trauma clinicianswhen use of rFVIIa is both appropriate and life-saving. As with other interventions in intensive care, it is likely that the greatest eff ect of rFVIIa will come if it is used early, and late administration is more likely to be futile. Better methods of identifying early those patients who are most likely to benefi t are needed to help guide the appropriate use of rFVIIa. Importantly, too, in contrast to prospective, randomized trials in older populations [3] , studies of rFVIIa in trauma have not demonstrated an increased risk of thromboembolic complications above the baseline [4, 6] . Th e risk of arterial thrombosis is probably related to the presence of occult endothelial disruption from specifi c injuries, making individual clinical assessment even more important.
Reactive restrictions to off -label use of rFVIIa may represent the loss of both the baby and the bathwater. We prefer to advocate respect for the judgment of clinicians who must make hard choices in the management of highrisk patients, and call for continued research to support their true need -a better understanding of which patients will benefi t from procoagulant therapies, and of the real incidence and severity of risks.
